Intravitreous bevacizumab treatment for macular edema due to central retinal vein occlusion

Current Eye Research

Volumn 37, Issue 9, 2012, Pages 818-822

  Axer Siegel, Ruth ^a,b   Dotan, Assaf ^a   Mimouni, Karin ^a,b   Bor, Elite ^a,b   Weinberger, Dov ^a,b   Bourla, Dan Haim ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bevacizumab; Central retinal vein occlusion; Macular edema

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; BLURRED VISION; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CORNEA EROSION; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MEDICAL RECORD REVIEW; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA TEAR; RETINITIS; REVIEW; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84864854240     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.678543     Document Type: Review

References (27)

1. Rogers S, McIntosh RL, Cheung N et al. International Eye Disease Consortium. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9.e1.
2. Cugati S, Wang JJ, Rochtchina E et al. Ten-year incidence of retinal vein occlusion in an older population: The Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726-732.
3. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
4. Park SP, Ahn JK, Mun GH. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. Retina (Philadelphia, Pa) 2010;30:281-286.
5. Noma H, Funatsu H, Mimura T et al. Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol 2011;95: 788-792.
6. Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol 2009;23:259-265.
7. Stahl A, Struebin I, Hansen LL et al. Bevacizumab in central retinal vein occlusion: A retrospective analysis after 2 years of treatment. Eur J Ophthalmol 2010;20:180-185.
8. Hung KH, Lee SM, Lee SY et al. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther 2010;26:85-90.
9. Wu WC, Cheng KC, Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye (Lond) 2009;23:2215-2222.
10. Tao Y, Hou J, Jiang YR et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond) 2010;24:810-815.
11. Chang LK, Spaide RF, Klancnik JM et al. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina (Philadelphia, Pa) 2011;31:821-828.
12. Brown DM, Campochiaro PA, Singh RP et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.e1.
13. Bressler NM, Schachat AP. Management of macular edema from retinal vein occlusions: You can never have too many choices. Ophthalmology 2010;117:1061-1063.
14. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432-3437.
15. Krebs I, Hagen S, Smretschnig E, et al. Conversion of Stratus optical coherence tomography (OCT) retinal thickness to Cirrus OCT values in age-related macular degeneration. Br J Ophthalmol (In Press).
16. Chopovska Y, Jaeger M, Rambow R et al. Comparison of central retinal thickness in healthy children and adults measured with the Heidelberg Spectralis OCT and the zeiss Stratus OCT 3. Ophthalmologica 2011;225:27-36.
17. Spaide RF. Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography. Retina (Philadelphia, Pa) 2011;31:829-837.
18. Ip MS, Scott IU, VanVeldhuisen PC et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
19. Haller JA, Bandello F, Belfort R Jr et al. OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.e3.
20. Kinge B, Stordahl PB, Forsaa V et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: Results from the sham-controlled ROCC study. Am J Ophthalmol 2010;150:310-314.
21. Algvere PV, Von Wendt G, Gudmundsson J et al. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin). Acta Ophthalmol 2010;88:836-841.
22. Ach T, Hoeh AE, Schaal KB et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:155-159.
23. Ehrlich R, Ciulla TA, Moss AM et al. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol 2010;248:375-380.
24. Zhang H, Liu ZL, Sun P et al. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: Eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 2011;27:615-621.
25. DeCroos FC, Ehlers JP, Stinnett S et al. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: Perfused vs. ischemic and early vs. late treatment. Curr Eye Res 2011;36:1164-1170.
26. Algvere PV, Epstein D, von Wendt G et al. Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol 2011;21:789-795.
27. Guthoff R, Meigen T, Hennemann K et al. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion - A matched-pairs analysis. Ophthalmologica 2010;224:126-132.